Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1418 | Soyasaponin II |
| 1. Soyasaponin II has antiviral effects, it can inhibit the replication of human cytomegalovirus, influenza virus, and human immunodeficiency virus type 1. 2. Soyasaponins II can inhibit the conversion of fibrinogen to fibrin, it also can promote activation of the fibrinolytic system in a plasminogen-containing fibrin plate. 3. Soyasaponin II has hepatoprotective actions towards immunologically induced liver injury on primary cultured rat hepatocytes. 4. Soyasaponins are a potential antitumor compound and the apoptosis induced by soyasaponins is a key antitumor mechanism. | |
| BCN1426 | 9,13-Epidioxy-8(14)-abieten-18-oic acid |
| 1. 9,13β-Epidioxy-8(14)-abieten-18-oic acid exhibits moderate activities on NO levels in LPS-stimulated murine microglia BV2 cells, with IC50 values of 57.3 ± 0.2 uM, suggests that it has anti-inflammatory activities. 2. 9α,13α-Epidioxyabiet-8(14)-en-18-oic acid shows potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate, suggests that it is a potential antitumor-promoting diterpenoid. 3. 9 α ,13 β -Epidioxyabeit-8(14)en-18-oic acid may contribute to the growth inhibitory effect of the pine needles and may play an important role in the allelopathy of red pine. | |
| BCN1528 | Isorhamnetin 3-glucoside-7-rhamnoside |
| 1. An anti-oxidative composition containing isorhamnetin-3-glucoside-7-rhamnoside (IGR)isolated from Hippophae rhamnoides L. is provided to ensure antioxidative, antibacterial, and anti-cancer effect; a cosmetic composition for preventing or treating aging contains IGR compound as an active ingredient; a health food composition for antioxiaiton contains IGR as an active ingredient; a pharmaceutical composition for antibacterial and anticancer contains IGR as an active ingredient. | |
| BCN1634 | Tamoxifen |
| 1. Tamoxifen acts as an estrogen agonist by preventing the skeletal alterations that result from ovarian hormone deficiency. 2. Tamoxifen is currently the first-line therapy for treatment of hormone-dependent breast cancer. | |
